Ariad Pharmaceuticals, Inc. to Outline Cost Cuts Next Week After Suspension of Iclusig Sales
Published: Nov 01, 2013
An Ariad Pharmaceuticals spokesman says cost reduction plans will be outlined next week after the company said Thursday it is temporarily suspending sales of its only approved drug in the wake of concerns that it may cause blood clots. The Cambridge drug company said Thursday morning in a statement that the U.S. Food and Drug Administration on Wednesday afternoon made “a request” that it halt marketing and distribution of the drug, which was approved on under accelerated approval last December to treat certain kinds of chronic myeloid leukemia after other drugs have failed.
Help employers find you! Check out all the jobs and post your resume.